EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients with Active Skin Manifestations

BOSTON--(BUSINESS WIRE)--Jul 8, 2026-- EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for …